469 related articles for article (PubMed ID: 35044098)
1. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study.
Luan Y; Zhang Y; Yu SY; You M; Xu PC; Chung S; Kurita T; Zhu J; Kim SY
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1289-1301. PubMed ID: 35044098
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia.
Pototschnig I; Feiler U; Diwoky C; Vesely PW; Rauchenwald T; Paar M; Bakiri L; Pajed L; Hofer P; Kashofer K; Sukhbaatar N; Schoiswohl G; Weichhart T; Hoefler G; Bock C; Pichler M; Wagner EF; Zechner R; Schweiger M
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):93-107. PubMed ID: 36351437
[TBL] [Abstract][Full Text] [Related]
3. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
4. Targeting interleukin-1 for reversing fat browning and muscle wasting in infantile nephropathic cystinosis.
Cheung WW; Hao S; Zheng R; Wang Z; Gonzalez A; Zhou P; Hoffman HM; Mak RH
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1296-1311. PubMed ID: 34196133
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia.
Cheung WW; Hao S; Wang Z; Ding W; Zheng R; Gonzalez A; Zhan JY; Zhou P; Li S; Esparza MC; Hoffman HM; Lieber RL; Mak RH
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):120-134. PubMed ID: 31721480
[TBL] [Abstract][Full Text] [Related]
6. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
7. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
8. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
9. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling.
Xu PC; You M; Yu SY; Luan Y; Eldani M; Caffrey TC; Grandgenett PM; O'Connell KA; Shukla SK; Kattamuri C; Hollingsworth MA; Singh PK; Thompson TB; Chung S; Kim SY
Sci Rep; 2022 Jan; 12(1):1659. PubMed ID: 35102236
[TBL] [Abstract][Full Text] [Related]
10. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk.
Wu J; Dong J; Verzola D; Hruska K; Garibotto G; Hu Z; Mitch WE; Thomas SS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1210-1227. PubMed ID: 31507080
[TBL] [Abstract][Full Text] [Related]
11. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
12. A Leptin Receptor Antagonist Attenuates Adipose Tissue Browning and Muscle Wasting in Infantile Nephropathic Cystinosis-Associated Cachexia.
Gonzalez A; Cheung WW; Perens EA; Oliveira EA; Gertler A; Mak RH
Cells; 2021 Jul; 10(8):. PubMed ID: 34440723
[TBL] [Abstract][Full Text] [Related]
13. The Extract of
Han YH; Mun JG; Jeon HD; Yoon DH; Choi BM; Kee JY; Hong SH
Nutrients; 2020 Oct; 12(10):. PubMed ID: 33086629
[TBL] [Abstract][Full Text] [Related]
14. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Zhou L; Zhang T; Shao W; Lu R; Wang L; Liu H; Jiang B; Li S; Zhuo H; Wang S; Li Q; Huang C; Lin D
Skelet Muscle; 2021 Jul; 11(1):17. PubMed ID: 34229732
[TBL] [Abstract][Full Text] [Related]
15. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
16. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia.
Lemecha M; Chalise JP; Takamuku Y; Zhang G; Yamakawa T; Larson G; Itakura K
Mol Metab; 2022 Dec; 66():101612. PubMed ID: 36243318
[TBL] [Abstract][Full Text] [Related]
17. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
18. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of metabolic dysfunction in cancer-associated cachexia.
Petruzzelli M; Wagner EF
Genes Dev; 2016 Mar; 30(5):489-501. PubMed ID: 26944676
[TBL] [Abstract][Full Text] [Related]
20. Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Matsuyama T; Ishikawa T; Okayama T; Oka K; Adachi S; Mizushima K; Kimura R; Okajima M; Sakai H; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Kokura S; Naito Y; Itoh Y
Int J Cancer; 2015 Dec; 137(11):2558-65. PubMed ID: 26016447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
